Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homoharringtonine for Refractory Acute Promyelocytic Leukemia
NCT00030355Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in acute promyelocytic leukemia (APL), sponsored by National Cancer Institute. Status: withdrawn.
02
Drugs
homoharringtonine
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00030355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030355.